Hepatic enhancement and signal intensity analysis on magnetic resonance imaging as prognostic biomarkers in advanced chronic liver disease

doi:10.4254/wjh.v17.i12.111418

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (49)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-9) series, Tables (1-13) series.

Item

Count

PDF

HTML

Figures (1-9)

Tables (1-13)

Sum=36

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=3

Dec 27, 2025 (publication date) through Dec 29, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Dec 27, 2025; 17(12): 111418
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.111418

Table 1 Functional Liver Imaging Score scoring criteria

Parameter	Score 0	Score 1	Score 2
Hepatic enhancement (liver signal intensity vs right kidney)	Hypointense	Isointense	Hyperintense
Biliary excretion (presence of contrast in biliary structures)	No excretion	Intrahepatic bile ducts	Common bile duct or duodenum
Portal vein signal (portal vein intensity vs liver parenchyma)	Hyperintense	Isointense	Hypointense

Full Size Table

Table 2 Biochemical and imaging characteristics of the study cohort

Parameter/score	mean ± SD
Platelets (× 10³/µL)	126.12 ± 73.48
AST (U/L)	62.65 ± 54.04
ALT (U/L)	43.61 ± 38.15
Total bilirubin (mg/dL)	2.40 ± 2.76
Sodium (mEq/L)	135.98 ± 4.03
Potassium (mEq/L)	4.18 ± 0.54
Creatinine (mg/dL)	0.86 ± 0.23
Albumin (g/dL)	3.64 ± 0.79
INR	1.37 ± 0.40
MELD 3.0 score	13.75 ± 6.14
ALBI score	-2.14 ± 0.83
FIB-4 index	6.58 ± 6.21
Native SI segment III	147.25 ± 26.15
Native SI segment VI	167.20 ± 24
Native SI segment VIII	153.90 ± 19.57
Native SI caudate lobe	161.91 ± 22.95
Native SI global	157.56 ± 21.28
Hepatobiliary SI segment III	230.75 ± 55.40
Hepatobiliary SI segment VI	262.60 ± 59.38
Hepatobiliary SI segment VIII	245.85 ± 50.18
Hepatobiliary SI caudate lobe	255.50 ± 57.92
Hepatobiliary SI global	248.68 ± 53.90
HE segment III	83.50 ± 37.16
HE segment VI	95.40 ± 43.01
HE segment VIII	91.95 ± 36.72
HE caudate lobe	93.59 ± 40.90
HE global	91.11 ± 38.15

ALBI: Albumin-Bilirubin score; ALT: Alanine aminotransferase; AST: Aspartate Aminotransferase; FIB-4: Fibrosis-4 score; HE: Hepatic enhancement; INR: International Normalized Ratio; MELD: Model for End-Stage Liver Disease; SD: Standard deviation; SI: Signal intensity.

Full Size Table

Table 3 Correlations among hepatobiliary signal intensity, Functional Liver Imaging Score, clinical scores, liver stiffness, and hepatic venous-portal gradient

Region	FLIS	Child-Pugh	MELD 3.0	ALBI	FIB-4	Liver stiffness	HVPG
SI segment III	0.661^a	-0.496^a	-0.521^a	-0.519^a	-0.222^a	-0.389^a	-0.167 (P = 0.208)
SI segment VI	0.763^a	-0.589^a	-0.623^a	-0.603^a	-0.268^a	-0.390^a	-0.267 (P = 0.094)
SI segment VIII	0.683^a	-0.463^a	-0.545^a	-0.493^a	-0.259^a	-0.422^a	-0.302 (P = 0.067)
SI caudate lobe	0.727^a	-0.532^a	-0.563^a	-0.562^a	-0.266^a	-0.461^a	-0.289 (P = 0.076)
Global SI	0.736^a	-0.540^a	-0.584^a	-0.565^a	-0.263^a	-0.429^a	-0.261 (P = 0.099)

^aP < 0.05.

ALBI: Albumin-bilirubin score; FIB-4: Fibrosis-4 index; FLIS: Functional Liver Imaging Score; HVPG: Hepatic venous-portal gradient; MELD: Model for End-Stage Liver Disease; SI: Signal intensity.

Full Size Table

Table 4 Association between hepatic enhancement and Functional Liver Imaging Score in the whole cohort and subgroups (no prior hepatocellular carcinoma, viral etiology, alcoholic etiology)

Region	F (ANOVA)	P value	Partial η²	Linear trend F	Linear trend P	Deviation F	Deviation P	Levene’s P
Full cohort (n = 100)
Segment VI	38.448	< 0.001	0.672	190.171	< 0.001	0.518	0.723	0.062
Segment VIII	18.960	< 0.001	0.502	91.378	< 0.001	0.855	0.494	0.246
Caudate lobe	24.369	< 0.001	0.565	120.883	< 0.001	0.240	0.915	0.340
Segment III	19.393	< 0.001	0.508	95.767	< 0.001	0.299	0.878	0.157
Global HE	28.060	< 0.001	0.599	138.949	< 0.001	0.337	0.852	0.072
Non-HCC subgroup (n = 80)
Segment VI	36.974	< 0.001	0.714	179.371	< 0.001	1.375	0.251	0.086
Segment VIII	16.262	< 0.001	0.524	77.487	< 0.001	0.956	0.437	0.457
Caudate lobe	23.305	< 0.001	0.612	114.939	< 0.001	0.396	0.811	0.429
Segment III	17.696	< 0.001	0.545	85.235	< 0.001	0.811	0.522	0.174
Global HE	26.237	< 0.001	0.639	128.016	< 0.001	0.792	0.534	0.125
Viral subgroup (n = 53)
Segment VI	15.968	< 0.001	0.571	61.566	< 0.001	0.769	0.517	0.017
Segment VIII	6.230	< 0.001	0.342	22.909	< 0.001	0.671	0.574	0.547
Caudate lobe	11.256	< 0.001	0.484	43.029	< 0.001	0.665	0.578	0.061
Segment III	8.940	< 0.001	0.426	34.033	< 0.001	0.576	0.634	0.152
Global HE	11.244	< 0.001	0.484	43.239	< 0.001	0.579	0.632	0.035
Alcoholic subgroup (n = 41)
Segment VI	22.325	< 0.001	0.761	103.808	< 0.001	1.955	0.123	0.751
Segment VIII	9.116	< 0.001	0.566	41.884	< 0.001	0.925	0.461	0.636
Caudate lobe	7.551	< 0.001	0.519	36.680	< 0.001	0.269	0.896	0.849
Segment III	8.439	< 0.001	0.566	38.439	< 0.001	0.938	0.453	0.174
Global HE	12.871	< 0.001	0.648	60.830	< 0.001	0.881	0.485	0.803

ANOVA: Analysis of Variance; HCC: Hepatocellular carcinoma; HE: Hepatic enhancement; P: Corresponding P-value for the omnibus analysis of variance test; Partial η²: Effect size index for analysis of variance; Linear trend F: F statistic for the test of linear trend across ordered categories; Linear trend P: Significant values suggest a consistent directional change; Deviation F: F statistic testing deviations from linearity; Deviation P: Values > 0.05 suggest no meaningful non-linear deviations; Levene’s P: Values > 0.05 indicate that the assumption of equal variances between groups is not violated.

Full Size Table

Table 5 Correlations among hepatic enhancement, Functional Liver Imaging Score, and clinical scores across the entire cohort and subgroups

Cohort	Region	FLIS	Child-Pugh	MELD 3.0	ALBI	FIB-4
Full cohort (n = 100)	HE segment VI	0.819^a	-0.611^a	-0.683^a	-0.624^a	-0.306^a
	HE segment VIII	0.718^a	-0.469^a	-0.584^a	-0.490^a	-0.300^a
	HE caudate lobe	0.765^a	-0.592^a	-0.634^a	-0.590^a	-0.312^a
	HE segment III	0.741^a	-0.580^a	-0.625^a	-0.579^a	-0.253^a
	Global HE	0.797^a	-0.589^a	-0.658^a	-0.599^a	-0.308^a
Non-HCC (n = 80)	HE segment VI	0.858^a	-0.616^a	-0.649^a	-0.624^a	-0.301^a
	HE segment VIII	0.716^a	-0.475^a	-0.551^a	-0.463^a	-0.278^a
	HE caudate lobe	0.790^a	-0.601^a	-0.599^a	-0.576^a	-0.302^a
	HE segment III	0.761^a	-0.582^a	-0.583^a	-0.568^a	-0.265^a
	Global HE	0.820^a	-0.596^a	-0.622^a	-0.591^a	-0.301^a
Viral (n = 53)	HE segment VI	0.656^a	-0.423^a	-0.574^a	-0.444^a	-0.287^a
	HE segment VIII	0.589^a	-0.320^a	-0.542^a	-0.410^a	-0.287^a
	HE caudate lobe	0.633^a	-0.456^a	-0.533^a	0.485^a	-0.342^a
	HE segment III	0.610^a	-0.471^a	-0.631^a	-0.530^a	-0.312^a
	Global HE	0.649^a	-0.433^a	-0.594^a	-0.485^a	-0.318^a
Alcoholic (n = 41)	HE segment VI	0.834^a	-0.603^a	-0.611^a	-0.594^a	-0.148 (q = 0.418)
	HE segment VIII	0.714^a	-0.412^a	-0.431^a	-0.396^a	-0.198 (q = 0.269)
	HE caudate lobe	0.739^a	-0.537^a	-0.513^a	-0.476^a	-0.074 (q = 0.682)
	HE segment III	0.707^a	-0.530^a	-0.414^a	-0.458^a	-0.013 (q = 0.936)
	Global HE	0.796^a	-0.546^a	-0.531^a	-0.511^a	-0.123 (q = 0.492)

^aq ≤ 0.05.

Values are Spearman’s ρ/q-value after false discovery rate-adjusted results (Benjamini-Hochberg procedure). ALBI: Albumin-Bilirubin score; FIB-4: Fibrosis-4 Index; FLIS: Functional liver imaging score; HCC: Hepatocellular carcinoma; HE: Hepatic enhancement; MELD 3.0: Model for End-Stage Liver Disease 30.

Full Size Table

Table 6 Correlations among hepatic enhancement, liver stiffness, and hepatic venous-portal gradient across the entire cohort and subgroups

Cohort	Region	Liver stiffness (ρ/q)	HVPG (ρ/q)
Full cohort (n = 100)	HE segment VI	-0.428/0.002^a	-0.345/0.049^a
	HE segment VIII	-0.503/0.001^a	-0.389/0.042^a
	HE caudate lobe	-0.477/0.001^a	-0.362/0.049^a
	HE segment III	-0.418/0.002^a	-0.232/0.127
	Global HE	-0.470/0.001^a	-0.340/0.049^a
Non-HCC (n = 80)	HE segment VI	-0.358/0.014^a	-0.200/0.261
	HE segment VIII	-0.470/0.003^a	-0.235/0.255
	HE caudate lobe	-0.447/0.003^a	-0.169/0.261
	HE segment III	-0.399/0.008^a	-0.049/0.416
	Global HE	-0.430/0.003^a	-0.167/0.261
Viral (n = 53)	HE segment VI	-0.211/0.127	0.160/0.492
	HE segment VIII	-0.328/0.059	-0.081/0.492
	HE caudate lobe	-0.217/0.120	-0.042/0.492
	HE segment III	-0.323/0.059	0.071/0.492
	Global HE	-0.286/0.120	0.093/0.492
Alcoholic (n = 41)	HE segment VI	-0.513/0.022^a	-0.552/0.061
	HE segment VIII	-0.604/0.020^a	-0.533/0.061
	HE caudate lobe	-0.533/0.020^a	-0.508/0.061
	HE segment III	-0.455/0.038^a	-0.433/0.092
	Global HE	-0.552/0.020^a	-0.524/0.061

^aq ≤ 0.05.

Values are Spearman’s ρ/q-value after false discovery rate-adjusted results (Benjamini-Hochberg procedure). Hepatic venous-portal gradient analyses restricted to patients with invasive measurements (n = 26). HCC: Hepatocellular carcinoma; HE: Hepatic enhnancement; HVPG: Hepatic venous-portal gradient; ρ: Correlation coefficient.

Full Size Table

Table 7 Global hepatic enhancement variation by clinical outcomes across the whole cohort and subgroups

Cohort	Outcome	Group	Mean HE ± SD	t (df)	P value	q value	Cohen’s d
Full cohort (n = 100)	HCC development	No HCC	87.48 ± 37.86	-1.662 (98)	0.100	0.100	0.384
	HCC development	HCC	102 ± 37.71	-1.662 (98)	0.100	0.100	0.384
	Decompensation	No decompensation	100.87 ± 34.30	3.526 (98)	0.001^a	0.003^a	0.717
	Decompensation	Decompensation	74.48 ± 39.07	3.526 (98)	0.001^a	0.003^a	0.717
	Mortality	Survivor	94.34 ± 36.65	2.231 (98)	0.028^a	0.042^a	0.625
	Mortality	Dead	69.52 ± 42.47	2.231 (98)	0.028^a	0.042^a	0.625
Non-HCC (n = 80)	HCC development	No HCC	81.12 ± 37.64	-1.448 (78)	0.152	0.152	0.379
	HCC development	HCC	95 ± 35.45	-1.448 (78)	0.152	0.152	0.379
	Decompensation	No decompensation	93.66 ± 33.63	2.478 (78)	0.015^a	0.026^a	0.552
	Decompensation	Decompensation	73.50 ± 39.16	2.478 (78)	0.015^a	0.026^a	0.552
	Mortality	Survivor	95.26 ± 37.02	2.622 (78)	0.011^a	0.033^a	0.941
	Mortality	Dead	63 ± 31.29	2.622 (78)	0.011^a	0.033^a	0.941
Viral cirrhosis (n = 53)	HCC development	No HCC	98.44 ± 37.70	-1.713 (51)	0.093	0.140	0.517
	HCC development	HCC	116.69 ± 32.74	-1.713 (51)	0.093	0.140	0.517
	Decompensation	No decompensation	105.57 ± 34.89	1.293 (51)	0.202	0.303	0.368
	Decompensation	Decompensation	91.56 ± 39.24	1.293 (51)	0.202	0.303	0.368
	Mortality	Survivor	105.99 ± 34.54	1.181 (51)	0.243	0.243	0.448
	Mortality	Dead	83.44 ± 62.18	1.181 (51)	0.243	0.243	0.448
Alcoholic cirrhosis (n = 41)	HCC development	No HCC	77.57 ± 33.92	0.523 (39)	0.604	0.604	0.218
	HCC development	HCC	70.78 ± 28.05	0.523 (39)	0.604	0.604	0.218
	Decompensation	No decompensation	94.49 ± 27.14	5.523 (39)	0.001^a	0.003^a	1.095
	Decompensation	Decompensation	61.57 ± 32.72	5.523 (39)	0.001^a	0.003^a	1.095
	Mortality	Survivor	79.88 ± 32.01	1.357 (39)	0.182	0.273	0.505
	Mortality	Dead	63.33 ± 33.40	1.357 (39)	0.182	0.273	0.505

^aP/q ≤ 0.05.

Values are Spearman’s q-value after false discovery rate-adjusted results (Benjamini-Hochberg procedure). Cohen’s d: Effect size; df: Degrees of freedom; HCC: Hepatocellular carcinoma; HE: Hepatic enhancement; SD: Standard deviation; t: t statistic.

Full Size Table

Table 8 Cox regression analyses for prediction of decompensation and mortality (per 10-unit hepatic enhancement increase)

Model	Endpoint	Predictor	HR (95%CI)	P (raw)	q (FDR)
Univariate	Decompensation	HE segment VI	0.77 (0.70-0.85)	< 0.001	< 0.001
		HE segment VIII	0.81 (0.73-0.90)	< 0.001	< 0.001
		HE segment III	0.79 (0.70-0.88)	< 0.001	< 0.001
		HE caudate lobe	0.79 (0.72-0.87)	< 0.001	< 0.001
		HE global	0.77 (0.69-0.86)	< 0.001	< 0.001
	Mortality	HE segment VI	0.78 (0.68-0.90)	< 0.001	0.004
		HE segment VIII	0.86 (0.74-1.01)	0.065	0.065
		HE segment III	0.75 (0.62-0.90)	0.002	0.005
		HE caudate lobe	0.80 (0.69-0.93)	0.004	0.005
		HE global	0.79 (0.67-0.93)	0.004	0.005
Adjusted (MELD3.0, etiology, prior HCC)¹	Decompensation	HE segment VI	0.87 (0.77-0.99)	0.029	0.145
		HE segment VIII	0.93 (0.83-1.05)	0.248	0.310
		HE segment III	0.91 (0.80-1.04)	0.178	0.237
		HE caudate lobe	0.92 (0.81-1.04)	0.178	0.237
		HE global	0.89 (0.79-1.02)	0.108	0.180
	Mortality	HE segment VI	0.87 (0.69-1.09)	0.227	0.695
		HE segment VIII	1.07 (0.87-1.30)	0.417	0.695
		HE segment III	0.88 (0.69-1.11)	0.284	0.710
		HE caudate lobe	0.97 (0.78-1.20)	0.733	0.733
		HE global	0.94 (0.74-1.20)	0.627	0.783

¹Multivariable models adjusted for Model for End-Stage Liver Disease 3.0, etiology, and prior hepatocellular carcinoma.

CI: Confidence interval; FDR: False discovery rate; HCC: Hepatocellular carcinoma; HE: Hepatic enhancement; HR: Hazard ratio; MELD: Model for End-Stage Liver Disease.

Full Size Table

Table 9 Diagnostic performance of hepatic enhancement, Functional Liver Imaging Score, and clinical scores for predicting decompensation: Receiver operating characteristic curve analysis results¹

Marker	AUC (95%CI)	Youden cut-off	Se	Sp	PPV	NPV	Δ HE vs FLIS (q)	Δ HE vs MELD 3.0 (q)	Δ HE vs ALBI (q)
FLIS	0.79 (0.69-0.88)	4.5	0.76	0.76	0.57	0.88	-	-	-
MELD 3.0	0.73 (0.63-0.86	18.5	0.43	0.94	0.8	0.74	-	-	-
ALBI	0.77 (0.68-0.86	-2.1	0.70	0.73	0.60	0.81	-	-	-
HE segment VI	0.74 (0.62-0.85)	75	0.68	0.86	0.64	0.88	-0.05 (0.123)	0.01 (0.964)	-0.04 (0.580)
HE segment VIII	0.68 (0.55-0.79)	67.5	0.43	0.86	0.64	0.72	-0.08 (0.014)	-0.05 (0.400)	-0.09 (0.400)
HE segment III	0.68 (0.56-0.79)	65	0.51	0.82	0.63	0.74	-0.08 (0.003)	-0.05 (0.400)	-0.09 (0.400)
HE caudate lobe	0.70 (0.59-0.81)	82.5	0.60	0.76	0.60	0.76	-0.11 (0.017)	-0.03 (0.616)	-0.07 (0.400)
HE global	0.71 (0.60-0.82)	86.3	0.70	0.71	0.59	0.81	-0.11 (0.023)	-0.02 (0.671)	-0.06 (0.400)

¹q: P-values adjusted using false discovery rate via the Benjamini-Hochberg test. False discovery rate-significant at q ≤ 0.05.

Δ: Area under the curve difference; ALBI: Albumin-Bilirubin score; AUC: Area under the curve; CI: Confidence interval; FLIS: Functional Liver Imaging Score; HE: Hepatic enhancement; MELD 3.0: Model for End-Stage Liver Disease 3.0; NPV: Negative predictive value; PPV: Positive predictive value; Se: Sensitivity; Sp: Specificity.

Full Size Table

Table 10 Receiver operating characteristic curve analysis results for the diagnostic performance of hepatic enhancement, Functional Liver Imaging Score, and clinical scores in predicting mortality¹

Marker	AUC (95%CI)	Youden cut-off	Se	Sp	PPV	NPV	Δ HE vs FLIS (q)	Δ HE vs MELD 3.0 (q)	Δ HE vs ALBI (q)
FLIS	0.81 (0.69-0.93)	4.5	0.92	0.64	0.28	0.98	-	-	-
MELD 3.0	0.79 (0.64-0.94)	15.5	0.77	0.75	0.31	0.96	-	-	-
ALBI	0.82 (0.69-0.95)	-1.4	0.69	0.85	0.41	0.95	-	-	-
HE segment VI	0.74 (0.57-0.91)	75	0.85	0.74	0.32	0.97	-0.07 (0.293)	-0.05 (0.369)	-0.08 (0.220)
HE segment VIII	0.64 (0.46-0.82)	75	0.62	0.74	0.26	0.93	-0.18 (0.025)	-0.15 (0.082)	-0.18 (0.081)
HE segment III	0.71 (0.56-0.87)	87.5	0.77	0.69	0.28	0.95	-0.09 (0.188)	-0.08 (0.267)	-0.11 (0.220)
HE caudate lobe	0.71 (0.55-0.87)	82.5	0.77	0.69	0.27	0.95	-0.09 (0.140)	-0.08 (0.220)	-0.11 (0.170)
HE global	0.71 (0.54-0.88)	86.3	0.85	0.62	0.25	0.96	-0.17 (0.140)	-0.08 (0.220)	-0.11 (0.170)

¹q: P-values adjusted using false discovery rate via the Benjamini-Hochberg test. False discovery rate-significant at q ≤ 0.05.

Δ: Area under the curve difference; ALBI: Albumin-bilirubin score; AUC: Area under the curve; CI: Confidence interval; FLIS: Functional Liver Imaging Score; HE: Hepatic enhancement; MELD 3.0: Model for End-Stage Liver Disease 3.0; NPV: Negative predictive value; PPV: Positive predictive value; Se: Sensitivity; Sp: Specificity.

Full Size Table

Table 11 Incremental performance summary of hepatic enhancement models vs the reference model, n (%)

Endpoint	Horizon (months)	Added variable to reference model	Categorical NRI (95%CI)	NRI event¹	NRI Non-event¹	Continuous NRI % (95%CI)	ΔAUC²	ΔBrier²
Decompensation	12 months	+ HE segment VI	0.0 (-13.6; 12.9)	-	-	-13.6 (-58.7; 31.0)	-0.002	+0.001
	12 months	+ HE global	0.0 (-14.6; 14.3)	-	-	+0.34 (-44.3; 45.5)	-0.003	+0.0008
	24 months	+ HE segment VI	+2.9 (0.0; 7.6)	0.0	+2.9	+9.5 (-33.1; 51.2)	+0.002	-0.0006
	24 months	+ HE global	+7.1 (1.5; 13.9)	0.0	+7.1	+21.9 (-20.6; 62.4)	+0.0029	-0.00038
Mortality	12 months	+ HE segment VI	+30.7 (1.0; 68.8)	+28.6	+2.2	+13.7 (-68.0; 94.3)	+0.012	+0.0001
	12 months	+ HE global	+31.8 (2.0; 69.9)	+28.6	+3.2	+24.4 (-58.8; 107.4)	+0.011	-0.0011
	24 months	+ HE segment VI	+5.6 (-23.9; 35.6)	0.0	+5.6	+12.2 (-53.4; 76.6)	+0.012	+0.0005
	24 months	+ HE global	+6.7 (-24.4; 36.7)	0.0	+6.7	+41.1 (-26.3; 107.9)	+0.006	-0.0004

¹“-”: Component not required because total net reclassification improvement was 0. The reference model: Functional Liver Imaging Score + Model for End-Stage Liver Disease 3.0 + etiology + prior hepatocellular carcinoma status.

²Signs indicate change from the reference model; absolute values are provided in the text.

ΔAUC: Area under the curve of hepatic enhancement model - area under the curve of reference model; AUC: Area under the curve; CI: Confidence interval; ΔBrier: Brier score of hepatic enhancement model - Brier score of reference model; NRI: Net reclassification improvement; HE: Hepatic enhancement.

Full Size Table

Table 12 Quantitative decision-curve analysis at prespecified thresholds (hepatic enhancement models vs reference model)¹

Endpoint	Horizon (months)	Added variable to reference model	Threshold	ΔNB (95%CI)	Net reduction per 100
Decompensation	12 months	+ HE global	0.10	-0.0020 (-0.0056; 0.001)	-2
	24 months	+ HE global	0.10	+0.0011 (0.000; 0.0033)	1
	24 months	+ HE global	0.20	+0.0100 (0.0025; 0.020)	4
Mortality	12 months	+ HE segment VI	0.10	+0.0110 (0.000; 0.032)	10
	12 months	+ HE global	0.10	+0.0120 (0.000; 0.033)	11
	12 months	+ HE global	0.20	+0.0225 (0.000; 0.055)	9
	24 months	+ HE global	0.10	+0.0067 (0.0011; 0.0133)	6

¹The reference model: Functional Liver Imaging Score + Model for End-Stage Liver Disease 3.0 + etiology + prior hepatocellular carcinoma status. ΔNB is the net-benefit gain vs the reference model. “Net reduction per 100” translates ΔNB into fewer unnecessary interventions per 100 patients at the same true-positive yield.

CI: Confidence interval; NB: Net benefit; HE: Hepatic enhancement.

Full Size Table

Table 13 Intrareader agreement on region of interest measurements (n = 100)

Parameter	ICC	CV%	Bias	LoA (95%)
Native SI
Segment VI	0.927	3.2	-1.05	-18.57 to 16.47
Segment VIII	0.874	3.8	-3.50	-23.27 to 16.27
Caudate lobe	0.961	2.6	0.00	-12.61 to 12.61
Segment III	0.928	4.6	-0.35	-20.06 to 19.36
Global SI	0.955	2.3	-1.23	-13.77 to 11.32
Hepatobiliary SI
Segment VI	0.990	2.4	-0.20	-16.62 to 16.22
Segment VIII	0.990	2.2	-2.90	-16.84 to 11.04
Caudate lobe	0.993	1.8	0.20	-13.15 to 13.55
Segment III	0.988	3.2	-1.50	-18.19 to 15.19
Global SI	0.995	1.8	-1.10	-11.33 to 9.13
HE
Segment VI	0.955	14.9	0.85	-25.02 to 26.72
Segment VIII	0.941	12.1	0.60	-24.98 to 26.18
Caudate lobe	0.974	9.4	0.20	-18.22 to 18.62
Segment III	0.943	14.8	-1.15	-26.02 to 23.72
Global HE	0.974	9.3	0.12	-17.25 to 17.50

Bias: Mean difference between repeated measurements; CV: Coefficient of variation; HE: Hepatic enhancement; ICC: Intraclass correlation coefficient; LoA: Limits of agreement; SI: Signal intensity.

Full Size Table

Citation: Stanciu BI, Iojiban M, Morariu-Barb A, Caraiani C, Procopet B, Stefanescu H, Lupsor-Platon M. Hepatic enhancement and signal intensity analysis on magnetic resonance imaging as prognostic biomarkers in advanced chronic liver disease. World J Hepatol 2025; 17(12): 111418
URL: https://www.wjgnet.com/1948-5182/full/v17/i12/111418.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i12.111418